University of Sussex
Browse
Soares_et_al-2018-British_Journal_of_Dermatology.pdf (120.57 kB)

Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs

Download (120.57 kB)
journal contribution
posted on 2023-06-09, 12:43 authored by P Soares, Katy FidlerKaty Fidler, J Felton, R Tavendale, A Hövels, Stephen BremnerStephen Bremner, C N A Palmer, Somnath MukhopadhyaySomnath Mukhopadhyay
Background Eczema and asthma are chronic diseases with onset usually before the age of 5 years. More than 50% of individuals with eczema will develop asthma and/or other allergic diseases. Several loss-of-function mutations in filaggrin (FLG) have been identified in patients with eczema. However, the association of FLG with healthcare use is unknown. Objectives To determine whether FLG mutations are associated with increased prescribing for eczema and asthma and whether increased prescribing is associated with increased healthcare costs. Methods A secondary analysis of BREATHE, a cross-sectional study of gene–environment associations with asthma severity, was undertaken. BREATHE data was collected for 1100 participants with asthma, in Tayside and Fife, Scotland during the period 2003–2005. Through collaboration with the Health Informatics Centre in Dundee, BREATHE was linked to accident and emergency, community prescribing and Scottish morbidity records. The data linkage allowed longitudinal exploration of associations between genetic variation and prescribing. Results An association was found between FLG mutations and increased prescribing for mild and moderate eczema, asthma-reliever medicine and asthma exacerbations. A strong association was found between FLG mutations and prescribing of emollients [incidence rate ratio (IRR) 2·19, 95% confidence interval (CI) 1·36–3·52], treatment for severe eczema (IRR 2·18, 95% CI 1·22–3·91) and a combination of a long-acting ß2-agonist and corticosteroids (IRR 3·29, 95% CI 1·68–6·43). Conclusions The presence of FLG mutations in this cohort is associated with increased prescribing for eczema and asthma. Randomized controlled trials are required to determine if these individuals could benefit from management strategies to reduce morbidity and treatment costs.

History

Publication status

  • Published

File Version

  • Published version

Journal

British Journal of Dermatology

ISSN

1365-2133

Publisher

Blackwell Publishing

Issue

3

Volume

179

Page range

717-723

Department affiliated with

  • BSMS Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2018-04-05

First Open Access (FOA) Date

2018-08-15

First Compliant Deposit (FCD) Date

2018-04-04

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC